IgA transcytosis: A new weapon in the immune response to cancer?

Céline M Laumont; Brad H Nelson

doi:10.1016/j.ccell.2021.04.007

IgA transcytosis: A new weapon in the immune response to cancer?

Cancer Cell. 2021 May 10;39(5):607-609. doi: 10.1016/j.ccell.2021.04.007.

Authors

Céline M Laumont¹, Brad H Nelson²

Affiliations

¹ Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
² Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 3E6, Canada. Electronic address: [email protected].

PMID: 33974859
DOI: 10.1016/j.ccell.2021.04.007

Abstract

Tumor-infiltrating B cells and plasma cells have emerged as critical players in anti-tumor immunity. A recent report in Nature shows that IgA antibodies produced by these cells can enter tumor cells by transcytosis, impede oncogenic signals, and facilitate T cell-mediated cytotoxicity. These findings reveal a promising new mechanism to exploit for immunotherapy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunity
Immunoglobulin A
Immunotherapy
Neoplasms*
Transcytosis*

Substances

Immunoglobulin A

Grants and funding

429161/CIHR/Canada